NMRC Awards Ceremony and Research Symposium 2024

Prof Sir Peter Horby trained in medicine at University College London and went on to specialise in emerging and epidemic prone infectious diseases. Over the last 20 years he has led research on a wide range of emerging and epidemic infections, including SARS, avian influenza, Ebola, Lassa fever, plague and COVID-19.

Sir Peter is Director of the Pandemic Sciences Institute, an interdisciplinary research institute at the University of Oxford with a mission to discover, create and enable practical, science-driven solutions to infectious disease threats worldwide. He is also Executive Director of the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC), a consortium of 61 international, national and local research networks whose research activities span 141 countries worldwide.

Sir Peter co-leads the RECOVERY trial of treatments for COVID-19, which has randomised over 48,000 participants and evaluated 13 drugs. RECOVERY is open to recruitment in eight countries and has extended to include the evaluation of treatments for influenza and community acquired pneumonia.

Sir Peter is the Chair of the UK Government’s New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and a regular advisor to the World Health Organization.

Dr Amy P. Abernethy, MD, PhD was Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agency's acting Chief Information Officer from 2019-2021. As of April 2024, she is starting a new organisation focused on advancing clinical evidence generation. There, she will lead initiatives to inform health policy, demonstrate new capabilities in healthcare settings, and fund programs that drive innovation in clinical research; details are forthcoming.

Subsequent to Dr Abernethy’s role at FDA, she was President of Product Development and Chief Medical Officer at Verily, where she led teams in the development and delivery of solutions that bridge the gap between clinical research and care. Prior to FDA, she was Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Oncology of Flatiron Health. Before joining Flatiron, she was Professor of Medicine at Duke University School of Medicine and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute.

Dr Abernethy is a hematologist/oncologist and palliative medicine physician who has authored more than 500 publications. She holds a BA in Biochemistry from the University of Pennsylvania, an MD from Duke University School of Medicine, and a PhD from Flinders University in Australia.

Prof Uri Gneezy is the Epstein/Atkinson Endowed Chair in Behavioural Economics at the Rady School of Management, University of California, San Diego. As a researcher, he focuses on putting behavioural economics to work in the real world, where theory can meet application. He is looking for basic research as well as more applied approaches to the study of when and why incentives (don’t) work. His research covers topics such as incentives-based interventions to increase good habits and decrease bad ones, gender differences in reaction to incentives, and how incentives affect deception and ethical behaviour in general.

In addition to the traditional laboratory and field studies, Prof Gneezy is working with firms on using basic findings from behavioural economics to help companies achieve their traditional goals in non-traditional ways. His recent book is Mixed Signals: How Incentives Really Work.

Prof Haibo Wang is Director of Clinical Trial Unit, Vice Dean of Precision Medicine, First Affiliated Hospital of Sun Yat Sen University; and the executive Editor-in-Chief of Health Care Science, Institute for Hospital Management of Tsinghua University.

Prof Wang’s research focus on the intersection of data science and artificial intelligence in medicine. He has published more than 100 SCI publications including prestigious international journals like New England Journal of Medicine, Lancet and British Medical Journal.

Prof Rong Li came from Johns Hopkins University where she served as the Director of the Centre for Cell Dynamics in the Johns Hopkins School of Medicine. She was recruited to National University of Singapore (NUS) in 2019 as the second Director of Mechanobiology Institute (MBI).

Prof Li is a globally respected leader in the study of cellular dynamics and mechanics. Her interdisciplinary research integrates genetics, quantitative imaging, biophysical measurements, mathematical modelling, genomics and proteomics — to understand how eukaryotic cells transmit their genomes, adapt to the environment, and establish distinct organisation to perform specialised functions.

The diverse projects in Prof Li’s laboratory contribute to two main research thrusts: cell and tissue aging; cellular and organismal adaptation. The study on ageing focuses on understanding dynamic changes of crucial cellular components during the ageing process and how these changes alter the mechanical functions of cells and tissues. The insights gained will be applied to the development of new methods for prolonging healthy ageing and the repair and regeneration of deteriorated functions. The study of adaptation aims to understand the dynamics of genetic and epigenetic determinants of cells and tissues under acute or chronic stress which lead to adaptive behaviours ultimately beneficial or detrimental to the fitness of the organism. A potential application of the discoveries in this area is the prevention of cancer associated with chronic inflammatory diseases.

For more details on her lab, please visit: https://www.mbi.nus.edu.sg/rong-li/

Prof Sir Peter Horby trained in medicine at University College London and went on to specialise in emerging and epidemic prone infectious diseases. Over the last 20 years he has led research on a wide range of emerging and epidemic infections, including SARS, avian influenza, Ebola, Lassa fever, plague and COVID-19.

Sir Peter is Director of the Pandemic Sciences Institute, an interdisciplinary research institute at the University of Oxford with a mission to discover, create and enable practical, science-driven solutions to infectious disease threats worldwide. He is also Executive Director of the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC), a consortium of 61 international, national and local research networks whose research activities span 141 countries worldwide.

Sir Peter co-leads the RECOVERY trial of treatments for COVID-19, which has randomised over 48,000 participants and evaluated 13 drugs. RECOVERY is open to recruitment in eight countries and has extended to include the evaluation of treatments for influenza and community acquired pneumonia.

Sir Peter is the Chair of the UK Government’s New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and a regular advisor to the World Health Organization.

Dr Shum Cheuk Fan graduated from the National University of Singapore (NUS) and was conferred Master of Medicine (MMed Surgery). He attained his Fellowship of Academy of Medicine, Singapore (FAMS Urology) in 2015.

Dr Shum completed a Fellowship in Minimally Invasive Urology in Indiana University School of Medicine, Indiana, United States in 2017, which empowered him to perform urologic operations with least post-operative morbidities to his patients. Upon his return to Singapore, he became a strong advocate for the use of laparoscopic surgery for many urologic conditions and streamlined this service to meet international standards of care. In Aug 2019, he was awarded the Youth Section Fellowship, jointly by the Urological Association of Asia and the European Association of Urology, for his efforts in transforming minimally invasive urology for patients without access to the surgical robot.

With subspecialty interest in kidney cancer, Dr Shum published multiple scientific papers on the treatment and outcomes of renal masses. His publications can be found in top-tiered medical journals, such as the Journal of Endourology, and featured in online resource platforms for healthcare professionals and patients, such as UroToday®. Some of his clinical research areas include intra-operative fluorescence for accurate tumour identification during partial nephrectomy, prediction of renal function, impact of tumour margin status, and survival after partial nephrectomy. He received the Singapore National Medical Research Council Clinician Innovator Award in 2022 to expand the use of artificial intelligence in CT imaging of renal masses.

Dr Shum is also an enthusiastic teacher. He has been appointed Adjunct Assistant Professor by the NUS Yong Loo Lin School of Medicine, and Adjunct Lecturer by the Lee Kong Chian School of Medicine, Nanyang Technological University, since 2020. He served as examiners in various medical undergraduate and post-graduate examinations.

Prof Thomas M. Coffman is the Dean of Duke-NUS Medical School in Singapore and the James R. Clapp Professor of Medicine at Duke University School of Medicine. Before moving to Singapore, he held several leadership positions at Duke, including Chief of the Division of Nephrology, Vice-Chair of the Department of Medicine, and Founding Director of the Duke Cardiovascular Research Center. He was also the Founding Director of the Duke-NUS Cardiovascular and Metabolic Disorders Signature Research Program. He serves on the Boards of Directors for Singapore Health Services (SingHealth), the Singapore Eye Research Institute, the Singapore National Medical Research Council, and the King Faisal Specialty Hospital and Research Center in Saudi Arabia. He is also serving as the Chairman of the Medical Advisory Committee at the National Kidney Foundation (NKF) Singapore. An international leader in the field of nephrology, he was a Councilor and Past-President of the American Society of Nephrology and served as Treasurer for the International Society of Nephrology.

Prof Coffman is a member of the American Society for Clinical Investigation and the Association of American Physicians and served as a member of the Nephrology Subspecialty Board of the American Board of Internal Medicine. He has held a number of editorial positions including Associate Editor for the Journal of Clinical Investigation, and currently serves on the editorial advisory board of Cell Metabolism. He has been a productive researcher publishing over 200 scientific papers with h-index of 79, and he has been funded for many years by the US National Institutes of Health. His laboratory has made seminal contributions to understanding hypertension, the renin-angiotensin system, and diabetic nephropathy. In 2014, he received the Excellence Award for Hypertension Research from the American Heart Association. He currently serves as the lead investigator for DYNAMO (Diabetes studY of Nephropathy And other Microvascular cOmplications), a S$25M Large Collaborative Grant funded by the Singapore National Medical Research Council.

Prof Jerry Chan Kok Yen read medicine at Trinity College Dublin, trained in the United Kingdom in Obstetrics and Gynaecology and completed a PhD in fetal stem cell transplantation at Imperial College London before setting up the Experimental Fetal Medicine Group in 2005. He splits his time between both clinical and translational research at KKIVF Centre.

Prof Chan’s research straddles several fields of cutting-edge science underpinning advances in reproductive biology, from early fetal development and immunology, to fetal therapy and perinatal advancements through optimising fertility and perinatal outcome. His lab seeks to translate discoveries from the laboratory and clinical arena into clinical applications to improve patient outcomes.

Prof Tan Eng King is the Deputy Chief Executive Officer (Academic Affairs), and Senior Consultant with the Department of Neurology, National Neuroscience Institute. He is also a Professor at the Duke-NUS Medical School and Lee Kong Chian School of Medicine.

Prof Tan has authored more than 600 peer-reviewed papers and book chapters on clinical and neuroimaging studies, functional genomics and experimental therapeutics in Movement Disorders.

Prof Tan has broad research interest including epidemiology, neuroimaging, clinical and functional genomics and experimental therapeutics in Parkinson’s disease, essential tremor and other movement disorders.

Prof Uri Gneezy is the Epstein/Atkinson Endowed Chair in Behavioural Economics at the Rady School of Management, University of California, San Diego. As a researcher, he focuses on putting behavioural economics to work in the real world, where theory can meet application. He is looking for basic research as well as more applied approaches to the study of when and why incentives (don’t) work. His research covers topics such as incentives-based interventions to increase good habits and decrease bad ones, gender differences in reaction to incentives, and how incentives affect deception and ethical behaviour in general.

In addition to the traditional laboratory and field studies, Prof Gneezy is working with firms on using basic findings from behavioural economics to help companies achieve their traditional goals in non-traditional ways. His recent book is Mixed Signals: How Incentives Really Work.

A/Prof Dan Yock Young obtained his medical degree (MBBS) from the National University of Singapore in 1994 and PhD in 2010. He is a gastro/hepatologist and clinician scientist with research interests in Non-Alcoholic fatty liver, liver stem cells and cost effectiveness.

A/Prof Dan is currently Senior Consultant at National University Health System and serves as Chief Executive Officer of Jurong Health Campus. Prior to this, he was Deputy Director-General of Health (Health Services Group) at the Ministry of Health overseeing healthcare services organisation and care model transformation.

Prof Roger Foo is the inaugural Zayed bin Sultan Al Nahyan Professor of Medicine and Vice Dean (Research) at the National University of Singapore (NUS) Yong Loo Lin School of Medicine; Director, NUHS Cardiovascular Disease Translational Research Programme, and Senior Consultant (Genetics lead), National University Heart Centre, Singapore. He is a graduate of the NUS Yong Loo Lin School of Medicine, and spent 20 years abroad before returning to Singapore in 2013. His specialist training was undertaken at King’s College Hospital, London, and Addenbrooke’s Hospital, Cambridge.

In 2003, Prof Foo was awarded the Wellcome Trust Fellowship to pursue research at the Albert Einstein College of Medicine, New York, and returned to Cambridge in 2006 as a British Heart Foundation Fellow and Consultant Physician, before eventually returning to Singapore. His laboratory was the first to publish an epigenomic map of the failing human heart in 2012. More recently, they have published an in-depth analysis of the cardiac chromatin 3D organisation, and also reported the discovery of nodal pathways that regulate key cardiac gene expression, and cardiomyocyte cell states. The approach of the lab deep dives into the cardiac genome, epigenome, using advanced technology including single cell transcriptomics and CRISPR-editing to explore frontiers.

Always seeking translational opportunities, Prof Foo was also the first to apply Next Generation sequencing based genomics to the cardiac clinic at National University Hospital, and established multiple research and commercial networks with collaborators locally and internationally. He holds an Adjunct Research Director position at the Institute of Molecular and Cell Biology in Agency for Science, Technology and Research (A*STAR), and mentors many young clinician scientists through his role as Head of the National University Health System Clinician Scientist Academy.

A/Prof Kavita Venkataraman is currently an Associate Professor at the Saw Swee Hock School of Public Health, National University of Singapore. She was previously with the World Health Organization Country Office for India.

A/Prof Venkataraman is a clinician, epidemiologist, and health services researcher, with research interests in the areas of cardiometabolic diseases with a specific focus on diabetes and its complications, rehabilitation care, care integration, patient perspectives of care, and patient-reported outcomes. She has authored several articles in reputed international journals, has several competitively funded research projects, completed and ongoing in these areas, and is currently a recipient of the Singapore National Medical Research Council Senior Clinician Scientist Award.

A/Prof Venkataraman has worked closely with national (Ministry of Health, public health clusters), and international (Indonesia, Malaysia, Thailand, the Philippines, and the UK) partners, with the goal of effectively translating research evidence into effective policies and programmes. Within the school, she is involved in undergraduate medical and non-medical, graduate, and doctoral student teaching on the topics of non-communicable diseases and research methods. In addition, she actively supports and mentors the next generation of public health practitioners and researchers in her areas of interest.

Prof Carolyn Lam is a Professor at Duke-NUS Medical School and Senior Consultant at the National Heart Centre Singapore specialising in heart failure and recognised globally for expertise in heart failure with preserved ejection fraction. In the field of MedTech, she is co-founder of Us2.ai, an award-winning startup dedicated to the automation of the fight against heart disease by applying artificial intelligence to echocardiography (ultrasound of the heart).

Prof Lam is a world-renowned clinical trialist, with her work as part of the global steering committee of the PARAGON and EMPEROR-Preserved trials contributing to the first FDA-approved treatment for HFpEF as well as the first robustly positive outcomes trial in HFpEF to date. For more details on the treatment, please visit: https://www.ajmc.com/view/entresto-wins-first-fda-nod-in-hard-to-treat-type-of-heart-failure

Prof Lam’s leadership in the field is recognised in her appointment to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force. She is a recipient of the Singapore National Medical Research Council Clinician Scientist Award (Senior Investigator category), Founding Programme Lead of A*STAR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-Heart Failure (ASIAN-HF; a multinational study across 11 Asian countries), and Executive Committee member/ lead of multiple global clinical trials.

Prof Lam has published >560 articles in journals including NEJM, JAMA, Lancet, Circulation, and European Heart Journal; and has been recognised in the Clarivate Highly cited Researcher 2021-2023 (source: https://www.webofscience.com/wos/author/record/ABD-6810-2021) and as a World Expert by Expertscape’s PubMed-based algorithms (top 0.1%o f scholars writing about Heart Failure over the past 10 years (source: https://www.expertscape.com/ex/heart+failure). She is lead author of the chapter on HFpEF for Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Edition and her achievements were recognized in nominations as the European Society of Cardiology (ESC) Rene Laennec Lecturer in Clinical Cardiology in 2022, Heart Failure Society of America (HFSA) 2023 Mihai Gheorghiade Lectureship and Singapore Cardiac Society Lecturer 2024.

Prof Lam serves as Deputy Editor of JACC and JACC: Heart Failure and previously as Associate Editor for Circulation and the European Journal of Heart Failure. Finally, she is familiar to the Singapore public as the Resident Doctor of the health television programme “Body and Soul” by MediaCorp Singapore for 10 seasons, and familiar to the medical community at large as the host of the weekly worldwide podcast “Circulation On The Run”.

Prof Haibo Wang is Director of Clinical Trial Unit, Vice Dean of Precision Medicine, First Affiliated Hospital of Sun Yat Sen University; and the executive Editor-in-Chief of Health Care Science, Institute for Hospital Management of Tsinghua University.

Prof Wang’s research focus on the intersection of data science and artificial intelligence in medicine. He has published more than 100 SCI publications including prestigious international journals like New England Journal of Medicine, Lancet and British Medical Journal.

Dr Jonathan Ng has been working to narrow gaps in healthcare outcomes for over 20 years, from working towards building Cambodia's first paediatric hospitals after the Khmer Rouge starting in 2005 and then training as a physician at the National University of Singapore (NUS) Yong Loo Lin School of Medicine where he graduated with honours as the Sir Arthur Gordon Ransome Prize and Award winner in Medicine. His mission has led him down a less trodden pathway of establishing Optimimed - a startup focused on reducing MRI wait times in Singapore, to pursuing multiple degrees at Massachusetts Institute of Technology and Harvard before spinning out his second company, Iterative Health.

Iterative Health is the largest AI in gastrointestinal (GI) company in the US, having raised over $200M and with a footprint stretching throughout the US, Dr Ng has been executing heavily on his vision to use AI technology to cross barriers in knowledge dispersion, enabling critical care to reach patients in GI at the right time.

A/Prof Daniel Ting is a senior consultant vitreo-retinal surgeon working in the Singapore National Eye Centre (SNEC), an Associate Professor with Duke-NUS Medical School and an Adjunct Clinical Associate Professor and an Innovation Mentor at Stanford University. He is also the Director of Singapore Health Service (SingHealth) AI Office, SNEC Chief Data and Digital Officer, and the Head of AI and Digital Innovation in Singapore Eye Research Institute (SERI). In 2017, he was US- ASEAN Fulbright Scholar visiting the Johns Hopkins University Fulbright Scholar to share his expertise in AI and big data in medicine. In addition to that, his research focus spans across not only on the technical aspect on machine learning, deep learning, large language models, explainable AI, privacy preserving technologies, but also safe, responsible and ethical clinical AI applications. He is also involved in several international consensus reporting guidelines such as STARD-AI, QUADAS-AI and DECIDE-AI.

To date, A/Prof Ting has published >250 publications on peer reviewed, book chapters, educational articles and conference abstracts. Of those, 45 were published in high impact journals (IF >10) such as JAMA, NEJM, Lancet, Nature Medicine, Nature Biomedical Engineering, Lancet Digital Health, Progress in Retinal and Eye Research, Diabetes Care, Nature Digital Medicine, Ophthalmology and etc. As of January 2024 (Google Scholar), his current H index: 58, i-10 index: 148 with total citations of >16696. One of his COVID-19 articles was published in Nature Medicine (1st author), entitled “Digital Technology and COVID-19” has so far been cited for >1100 times with >110,000 views, and also been referenced by the US Center for Disease Control and Prevention (Source:https://blogs.cdc.gov/genomics/2020/04/06/using-digital/). He has received a total of S$100M research grants, in which S$20M as a principal investigator, and S$80M as co-investigators on AI and digital innovation related projects in health.

A/Prof Ting serves in several leadership positions at the different AI and eye societies, including the American Academy of Ophthalmology AI and Retina Ophthalmology Technology Assessment committees, and he also chairs the AI and Digital Innovation Standing Committee for the Asia-Pacific Academy of Ophthalmology and Asia-Pacific Vitreo-Retinal Society. He also serves in numerous advisory and editorial boards in the top-tiered digital and medical journals, including Lancet Digital Health, Frontiers in Medicine, Frontiers in Digital Health and Asia-Pacific Journal of Ophthalmology; Section Editor in British Journal of Ophthalmology and Editorial Board Member in Ophthalmology, Ophthalmology Retina, Ophthalmology Science, British Journal of Ophthalmology, Asia-Pacific Journal of Ophthalmology and Retina.

For the accomplishment, A/Prof Ting was recognised by many top-tiered international AI and ophthalmology societies in winning many prestigious scientific awards, including Tatler Asia Gen T Award (2021), Singapore National Medical Research Council Clinician Scientist Award - Investigator category (2021), Asia-Pacific Academy Ophthalmology (APAO) Nakajima Award (2021), Asia-Pacific Vitreo-Retinal Society (APVRS) Ian Constable Award (2021), MICCAI OMIA Prestigious Achievement Award (2020), ARVO Bert Glaser Award for Innovative Research in Retina (2020), USA Macula Society Evangelos Gragoudas Award (2019), APAO Young Ophthalmologist’s Award (2018) and APTOS Young Innovator Award (2017).

In 2022 and 2023, A/Prof Ting is included in the World’s Top 100 Ophthalmologists Power list by the Ophthalmologists; and the World’s Top 2% Scientists by the Stanford University world ranking. In 2021, he was ranked 1st globally in the deep learning over the past decade (2010 – 2021), and has since been consecutively ranked top 10 worldwide for AI, machine learning and deep learning in science, engineering and health till to date.

Mr Chua Ming Jie serves as the Chief Executive Officer and Board Director of EVYD Technology, having founded the company in April 2020. Previously, he served as the Head of Corporate Finance and Capital Markets department at Yidu Tech.

Prior to EVYD Technology and Yidu Tech, Mr Chua oversaw the design and implementation of Investor Relations in the Capital Markets and Strategic Finance arm of Ant Group (formerly known as Ant Financial). Prior to his involvement in Ant Group, he worked at GIC Private Limited for seven years, with a focus on public equities.

Mr Chua earned a bachelor’s degree in Business Administration, majoring in Finance and Financial Mathematics from the National University of Singapore.

Prof Joseph Sung received his medical degree (MBBS) from The University of Hong Kong, and conferred PhD in biomedical sciences by the University of Calgary and MD by The Chinese University of Hong Kong (CUHK). He holds fellowships from the Royal Colleges of Physicians of Edinburgh, Glasgow, London, and Australia, the American College of Gastroenterology, the American Gastroenterological Association, the Hong Kong College of Physicians, the Hong Kong Academy of Medicine, Academy of Sciences of Hong Kong (ASHK), Japan Gastroenterological Endoscopy Society and Academy of Medicine, Singapore. He is an Academician of the Chinese Academy of Engineering of the People's Republic of China and Academician of the International Eurasian Academy of Sciences.

Prof Sung has published over 1000 full scientific articles in leading medical and scientific journals. He was listed as “Highly Cited Researchers”, released by the Clarivate Analytics, for the years 2018 to 2023. He has edited and authored over 30 books, as well as many chapters in major textbooks including the Oxford Textbook of Medicine (5th Ed.), Sleisenger & Fordtran's Gastrointestinal and Liver Disease (7th &8th Ed) and Yamada’s Textbook of Gastroenterology (4th Ed).

Prof Sung served as the Vice-Chancellor and President of the Chinese University of Hong Kong (2010 – 2017) and the Chair of Worldwide Universities Network (2016 - 2017).

Prof Sung is currently Distinguished University Professor, Senior Vice President (Health & Life Sciences) and Dean, Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore. He is also Emeritus Professor of Medicine at CUHK.

Dr Amy P. Abernethy, MD, PhD was Principal Deputy Commissioner of Food and Drugs of the US Food and Drug Administration (FDA) and the agency's acting Chief Information Officer from 2019-2021. As of April 2024, she is starting a new organisation focused on advancing clinical evidence generation. There, she will lead initiatives to inform health policy, demonstrate new capabilities in healthcare settings, and fund programs that drive innovation in clinical research; details are forthcoming.

Subsequent to Dr Abernethy’s role at FDA, she was President of Product Development and Chief Medical Officer at Verily, where she led teams in the development and delivery of solutions that bridge the gap between clinical research and care. Prior to FDA, she was Chief Medical Officer, Chief Scientific Officer and Senior Vice President of Oncology of Flatiron Health. Before joining Flatiron, she was Professor of Medicine at Duke University School of Medicine and directed the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute.

Dr Abernethy is a hematologist/oncologist and palliative medicine physician who has authored more than 500 publications. She holds a BA in Biochemistry from the University of Pennsylvania, an MD from Duke University School of Medicine, and a PhD from Flinders University in Australia.

Prof Derek Hausenloy is a Professor in the Cardiovascular & Metabolic Disorders Signature Program, Duke-National University of Singapore Medical School, and Research Director and Senior Consultant Cardiologist at the National Heart Research Institute, Singapore. He is a recipient of the Singapore National Medical Research Council Singapore Translational

Research (STaR) Investigator Award; who conducts basic, translational and clinical research in the areas of ischaemic heart disease, heart failure, cardioprotection, and cardiac MRI.

Prof Hausenloy is Executive Director of the CArdiovascular DiseasE National Collaborative Enterprise (CADENCE) National Clinical Translational Programme, a national platform for cardiovascular research with focus on data science, clinical trials and AI/digital health. He has been PI on over 40 research grants and has authored 368 papers (with 48,170 citations), and his H-index is 106. In 2018, 2020, 2021, 2022 and 2023 he was named Highly Cited Researcher by Clarivate Analytics (awarded to the top 1% of researchers worldwide).

A/Prof Daniel Tan is a Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS), an Associate Professor at Duke-National Medical School, and a Senior Clinical-Scientist at the Genome Institute of Singapore. He is also Head of the Division of Clinical Trials and Epidemiological Sciences, and Director of the Experimental Cancer Therapeutics Unit (Phase I Unit) at NCCS. He co-founded the Asian Thoracic Oncology Research Group and the Asian Pacific Drug Development Consortium to enable multi institutional collaborative research. A/Prof Tan’s research interests are in thoracic and head and neck oncology, and cancer drug development. His work is focused on improving the understanding of determinants of response and resistance to targeted therapy and immunotherapy.

A/Prof Tan has published more than 200 peer-reviewed articles, including Nature, Nature Medicine, Nature Genetics, New England Journal of Medicine and The Lancet. He has been the recipient of several national and international awards for his research, including the American Society of Clinical Oncology (ASCO) Merit Award twice, and in 2019, the International Association for the Study of Lung Cancer (IASLC) Daniel C. Idhe Lectureship Award for Medical Oncology. He serves as Associate Editor for the Journal of Thoracic Oncology as well as Scientific Editor for Cancer Discovery. He was previously co-chair for the World Conference in Lung Cancer (WCLC) in 2020, and the track chair for translational research at European Society for Medical Oncology (ESMO) 2021.